Orforglipron Comprehensive Forecast on the Accelerating Market Growth for Hypertension, Obesity, Sleep Apnea Syndrome and Type 2 Diabetes Mellitus by 2034

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Orforglipron providing insights into the drug market landscape and market forecast of Orforglipron upto 2034.

Are you interested in finding out the projected market size of Orforglipron in 2034? Orforglipron Market Forecast @ https://www.delveinsight.com/sample-request/orforglipron-sale-forecast-and-market-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Factors Driving Orforglipron Growth
1. Market Share Gains and New Patient Starts
• Orforglipron is not yet approved, so there are no "market share" numbers or "new patient starts" in the real world-but early clinical and regulatory data suggest strong potential.
• Phase III data (e.g. in ATTAIN-1, ACHIEVE-3) show it competes favorably with existing therapies (especially oral semaglutide), which could help it gain adoption quickly once approved.
• Lilly is preparing manufacturing, regulatory filings globally, anticipating strong demand.

2. Expansion across Key Indications
• Obesity / Weight Management: Orforglipron's Phase III trial ATTAIN-1 in non-diabetic obese or overweight adults (with weight-related medical conditions) showed clinically meaningful weight loss (up to ~12.4%) vs placebo over ~72 weeks.
• Type 2 Diabetes: In the ACHIEVE-3 trial, it significantly lowered HbA1c more than oral semaglutide at comparable doses, plus produced greater weight loss.
• Cardiometabolic risk factors: Improvements in non-HDL cholesterol, triglycerides, systolic blood pressure, and other markers have been observed.
• Other potential comorbid conditions are being explored (e.g. obesity with related complications) but full indication approvals are pending.

For More Information about Orforglipron Market Report @ https://www.delveinsight.com/sample-request/orforglipron-sale-forecast-and-market-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Orforglipron Market Report offers projected sales forecasts for Orforglipron for indications until 2034, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.

Orforglipron Drug Summary
Orforglipron is an investigational, once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake. Orforglipron was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018. Chugai and Lilly published the preclinical pharmacology data of this molecule together. Lilly is running Phase III studies on Orforglipron for the treatment of type 2 diabetes and for weight management in adults with obesity or overweight with at least one weight-related medical problem. It is also being studied as a potential treatment for obstructive sleep apnea and hypertension in adults with obesity. The report provides Orforglipron's sales, growth barriers and drivers, post usage and approvals in multiple indications. Orforglipron is in the Phase III stage of clinical development for the treatment of patients with Hypertension (NCT06948422), Obesity (NCT05931380), Sleep apnoea syndrome (NCT06649045), and Type 2 diabetes mellitus (NCT06010004).

Orforglipron Market Recent Developments
• In September 2025, Eli Lilly and Company announced positive topline results from ACHIEVE-3, an open-label randomized Phase III clinical trial evaluating the safety and efficacy of orforglipron compared to oral semaglutide, administered according to approved label instructions, in 1,698 adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial compared orforglipron (12 mg and 36 mg) to oral semaglutide (7 mg and 14 mg) across four active treatment arms to assess glycemic control and weight loss. At 52 weeks, orforglipron met the primary and all key secondary endpoints across each dose comparison vs. oral semaglutide, delivering greater improvements in A1C and weight.
• In August 2025, Eli Lilly and Company announced positive topline results from the Phase III ATTAIN-2 trial, evaluating orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes. In the trial, all three doses of orforglipron met the primary and all key secondary endpoints, delivering significant weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors at 72 weeks. For the primary endpoint, orforglipron 36 mg, taken once per day without food and water restrictions, lowered weight by an average of 10.5% (22.9 lbs) compared to 2.2% (5.1 lbs) with placebo using the efficacy estimand. With the completion of ATTAIN-2, Lilly now has the full clinical data package required to initiate global regulatory submissions for orforglipron.

Do you want to know more information of this report? @ https://www.delveinsight.com/sample-request/orforglipron-sale-forecast-and-market-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

What is Orforglipron Prescribed for?
Orforglipron is an investigational oral medication being developed primarily for the treatment of Type 2 Diabetes and Obesity. It works as a GLP-1 receptor agonist, helping regulate blood sugar levels by increasing insulin secretion, reducing glucagon release, and slowing gastric emptying. Additionally, it helps control appetite, which may support weight loss in individuals with obesity or overweight conditions. Unlike many GLP-1 therapies that require injections, orforglipron is designed as a once-daily oral treatment, making it a convenient option currently being evaluated in clinical studies for improving metabolic health and glycemic control.

Orforglipron Market Assessment
This report provides a detailed market assessment of Orforglipron for Hypertension, Obesity, Sleep Apnea Syndrome and Type 2 Diabetes Mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2020 to 2034.

Orforglipron Clinical Assessment
The report provides the clinical trials information of Orforglipron for Hypertension, Obesity, Sleep Apnea Syndrome and Type 2 Diabetes Mellitus covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.

Do you know your drug's competitive positioning against Orforglipron? Orforglipron Drugs Insights- https://www.delveinsight.com/sample-request/orforglipron-sale-forecast-and-market-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Orforglipron Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Orforglipron.

Orforglipron Market Size in the US
A dedicated section of the report focuses on the expected market size of Orforglipron for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Why you should buy Orforglipron Market Report
• The report provides future market assessments for Orforglipron for Hypertension, Obesity, Sleep Apnea Syndrome and Type 2 Diabetes Mellitus in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies.
• Leading Orforglipron for Hypertension, Obesity, Sleep Apnea Syndrome and Type 2 Diabetes Mellitus forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Orforglipron
• Discover the competitive landscape of Orforglipron through 7MM
• Get a Thorough Analysis of the Orforglipron Development pipeline, Safety & Efficacy of the Orforglipron, and ROA
• Thorough Orforglipron market forecast will help understand how drug is competing with other emerging Orforglipron
• Get analysis of the Orforglipron clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.